Next Science (ASX:NXS) share price jumps on record revenue growth

A surge in revenue during the first half of 2021 puts the Next Science share price in the green today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Next Science Ltd (ASX: NXS) share price is charging higher today.

At the time of writing, the medical technology company's shares are up 4.05% to $1.54.

medical doctor performing surgery using surgical instruments

Image source: Getty Images

Why is the Next Science share price rallying today?

Investors are looking at the Next Science share price more optimistically following the release of its second quarter update.

According to the release, the company pulled in US$3.9 million in revenue for the first half. This reflected an increase of 271% on the prior corresponding period.

Pleasingly for shareholders, this was a record rate of growth from Next Science.

Additionally, its XPerience No Rinse Antimicrobial Solution was cleared by the United States Food and Drug Administration.

The solution helps prevent surgical site biofilm based infections.

The approval process for use in US hospitals is now underway.

Furthermore, Next Science's antimicrobial wound gel, BlastX returned to the company and sales commenced.

Next Science regained the global distribution rights to BlastX from 3M (NYSE: MMM) in April 2021.

The patented medical product has also received approval from Australia's Therapeutic Goods Administration (TGA).

After burning through US$1.9 million in cash during the first half, the company maintains US$13.2 million cash on hand.

Managing Director commentary

Managing Director, Judith Mitchell spoke about the record result for the company:

The strategies we are executing to commercialise our proprietary Xbio technology platform are delivering record results. The 271% revenue growth we have reported for 1H was driven by sales from our existing products.

Following the approval of our market leading "no rinse antimicrobial solution", XPerience, by the FDA on 23 April, we are building an excellent platform for future growth. Our focus has been to secure VAC approvals across US hospitals to facilitate commercial sales in the US. As at mid-July, we had made 123 VAC submissions covering 211 hospitals and we had received 20 approvals.

Next Science share price snapshot

Thanks to today's gains, the Next Science share price is 18.46% higher over the past year.

However, investors who bought at the 52-week high of $2.06 in June are still down 25.24%.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Next Science Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another rough one for investors this Tuesday.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Guess which ASX rare earths stock just leapt 68% on big acquisition news

Investors are piling into the ASX rare earths miner today after it emerged from a lengthy trading halt.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Share Gainers

Why Elsight, IperionX, Predictive Discovery, and Reliance shares are pushing higher today

Let's see why investors are bidding these shares higher today.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing start to the trading week.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Atlas Arteria, Forrestania, Megaport, and WA1 shares are charging higher today

These shares are starting the week positively. But why?

Read more »

3 children standing on podiums wearing Olympic medals.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a lacklustre end to the trading week this Friday...

Read more »

three young children weariing business suits, helmets and old fashioned aviator goggles wear aeroplane wings on their backs and jump with one arm outstretched into the air in an arid, sandy landscape.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors sent these three ASX 200 stocks surging in this week’s tumbling market. But why?

Read more »

Worker on a laptop in front of an energy storage system in a factory.
Share Gainers

This ASX stock just landed a $110 million battery project. Shares near record highs.

Genusplus shares lift after a $110 million battery project win in South Australia...

Read more »